R&D | March 26, 2026
Zealand Pharma launches major US research hub in Cambridge, Massachusetts
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
Call it a major breakthrough for diagnostic imaging
The patent protects antiviral compounds developed by the company that inhibit Vacuolar ATPase (V-ATPase) activity in cells, a mechanism involved in viral infection pathways
The initiative will be led by David Baker, 2024 Nobel Prize winner in Chemistry, IPD director, professor of biochemistry, and HHMI Investigator at the University of Washington
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The move opens Japan’s advanced life science market to Epigenica’s high-throughput epigenetic profiling kits
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Subscribe To Our Newsletter & Stay Updated
